Nevanimibe - Millendo Therapeutics

Drug Profile

Nevanimibe - Millendo Therapeutics

Alternative Names: ATR-101

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer Millendo Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Acetyl CoA C-acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma; Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia; Cushing syndrome
  • Phase I Adrenocortical carcinoma

Most Recent Events

  • 17 Apr 2018 Adverse events data from a phase II trial in Congenital adrenal hyperplasia presented at the 100th Annual Meeting of the Endocrine Society (AMES-2018)
  • 08 Nov 2017 ATR 101 receives Orphan Drug status for Congenital adrenal hyperplasia in USA
  • 08 Nov 2017 Positive top-line safety and efficacy data from a phase II trial in Congenital adrenal hyperplasia released by Millendo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top